DDS, MSc, PhD, PGCAP, FHEA
Professor Georgios Belibasakis studied Dentistry at the Aristotle University of Thessaloniki, Greece (1999), attained a PhD in Oral Microbiology at Umeå University, Sweden (2004), an MSc in Periodontology (Distinction) at Queen Mary University of London (QMUL) (2009). He also holds a Postgraduate Certificate in Academic Practice (PGCAP) from QMUL (2009) and a Fellowship of the Higher Education Academy (FHEA), UK. He worked as post-doc at King’s College London (2005) and as a Lecturer in Oral Biology at QMUL (2005-2009), before moving to the University of Zürich (2009) to become Head of Section of Oral Microbiology and Immunology (2011) and attain his Habilitation (2012) and his first professorship in Oral Microbiology and Immunology (2014). In July 2016 he was appointed Professor of Clinical Oral Infection Biology and in July 2017 he became Head of the newly formed Division of Oral Diseases at the Department of Dental Medicine, Karolinska Institutet, Sweden, which encompasses the disciplines of Cariology, Endodontics, Periodontology and Dental Prevention. During January and February 2020 he was a Sir Thomas Kay Sidey Visiting Professor at the University of Otago, Dunedin, New Zealand.
He has authored more than 130 peer-reviewed publications in dental and biomedical journals, several textbook chapters and edited two textbooks. He organized the 12th European Oral Microbiology Workshop (EOWM) and the 1st International Conference on Oral Mucosal Immunity and Microbiome (Aegean Conferences). He serves as Specialty Chief Editor for Frontiers in Oral Health – Oral Infections and Microbes, Associate Editor for Archives of Oral Biology, BMC and Frontiers, and Editorial Board member in several journals. He is currently the Group Program Chair of the IADR Periodontal Research Group. His studies are of basic experimental and clinical translational scope, with focus on interactions between oral bacteria and the host for the establishment of infection, molecular bench-top and chair-side diagnostics for oral diseases, and novel antimicrobial approaches for their treatment.
